Table I:
Demographics and clinical characteristics of men with prostate cancer receiving care in the VHA between 2000–2015.
| Patient Characteristics | N=145,678 |
|---|---|
| Age (mean +/− SD) | 69.0 +/− 8.4 |
| No. Comorbidities (mean +/− SD) | 1.3 +/− 1.2 |
| Race/Ethnicity (%) | |
| White | 69.4 |
| Black | 26.2 |
| Other | 1.1 |
| Missing | 3.3 |
| Prostate Cancer Risk Category (%) | |
| Low Risk | 45.7 |
| Intermediate Risk | 16.6 |
| High Risk | 29.3 |
| Locally Advanced | 1.3 |
| Metastatic | |
| Gleason Score (%) | |
| <=6 | 61.7 |
| 7 | 14.3 |
| >=8 | 22.2 |
| Missing | 1.8 |
| PSA (%) | |
| < 10 | 59.8 |
| 10–20 | 17.7 |
| >20 | 9.3 |
| Missing | 13.2 |
| Clinical T Stage (%) | |
| T1 | 58.2 |
| T2 | 32.6 |
| T3 | 3.2 |
| T4 | 1.4 |
| Unknown | 4.7 |
| Clinical N Stage (%) | |
| N0 | 87.9 |
| N1 | 2.5 |
| NX | 9.7 |
| Clinical M Stage (%) | |
| M0 | 86.8 |
| M1 | 7.1 |
| MX | 6.1 |
| Initial Treatment (%) | |
| Surgery | 18.0 |
| Radiotherapy | 31.8 |
| Conservative | 24.1 |
| Androgen Deprivation | 16.1 |